FindTrial
Sign In

Analysis of factors associated with blood pressure reductions in hypertensive patients treated with esaxerenone -Integrated analysis from esaxerenone clinical studies-

Analysis of factors associated with blood pressure reductions in hypertensive patients treated with esaxerenone -Integrated analysis from esaxerenone clinical studies- - Integrated analysis from esaxerenone clinical studies

Status
Active, not recruiting
Phases
Unknown
Study type
Unknown
Source
JPRN
Registry ID
JPRN-UMIN000051525
Enrollment
493
Registered
2023-07-10
Start date
2023-07-10
Completion date
Unknown
Last updated
2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Hypertension

Interventions

None listed

Sponsors

Daiichi Sankyo Co., Ltd.
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria: Patients who were enrolled to esaxerenone clinical studies (5 studies in total)

Exclusion criteria

Exclusion criteria: Not applicable

Design outcomes

Primary

MeasureTime frame
Factors associated with change in morning BP (systolic BP and diastolic BP) from baseline to end of treatment (Week 12)—

Secondary

MeasureTime frame
Secondary endpoint; Factors associated with change in bedtime BP and office sitting BP (systolic BP and diastolic BP) from baseline to end of treatment (Week 12) Safety endpoint; Factors associated with number of patients with serum potassium elevation (5.5 mEq/L and more) to Week 12—

Countries

Japan

Contacts

Public ContactTakashi Taguchi

Daiichi Sankyo Co., Ltd. Primary Medical Science Department

taguchi.takashi.ft@daiichisankyo.co.jp03-6225-1111

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026